We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
SINNOWA MEDICAL SCIENCE & TECH

Nova Biomedical

Nova is a world leader in the development and manufacturing of whole blood, point-of-care and critical care analyzers... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
24 Feb 2021 - 28 Feb 2021
Virtual Venue
03 Mar 2021 - 05 Mar 2021
Virtual Venue

Nova Biomedical Adds PT/INR Test to Allegro Analyzer for POC Testing

By LabMedica International staff writers
Posted on 08 Apr 2020
Print article
Image: Nova Biomedical adds PT/INR test to Allegro analyzer for POC testing (Photo courtesy of Nova Biomedical)
Image: Nova Biomedical adds PT/INR test to Allegro analyzer for POC testing (Photo courtesy of Nova Biomedical)
Nova Biomedical (Waltham, MA, USA) has added PT/INR testing for its Allegro capillary blood analyzer for point-of-care (POC) testing in primary care settings. With the ability to test for clotting disorders and monitor the effectiveness of blood-thinning medications, the Allegro and its StatStrip-A companion meter provide 18 clinically important tests to help physicians make therapeutic decisions and adjustments at the POC.

Nova develops and manufactures whole blood, point-of-care and critical care analyzers, as well as provides advanced instruments for cell culture monitoring to the biotechnology industry. Nova’s Allegro is a compact, fast, and simple POC analyzer that features a clinically important menu of twelve measured and individually selectable tests, plus six calculated tests. All Allegro tests use easy capillary fingerstick sampling, eliminating the need for veni punctures or a trained phlebotomist, and easy-to-use disposable test cartridges or strips. Allegro’s quick six to nine-minute cartridge test times and ability to measure two cartridges simultaneously provide rapid results immediately to the physician, doubling throughput and improving efficiency.

Allegro's companion meters wirelessly transmit results to the analyzer, where they combine with all cartridge test results for one patient report. All results can be transmitted to electronic medical records for providers to review with patients during the visit. Having immediate results during the patient visit reduces clinic follow-up calls, letters, and patient re-visits, and improves patient satisfaction, compliance with care plans, and outcomes.

Allegro is the only analyzer that can measure HbAlc, lipids, glucose, and creatinine from a capillary sample. The latest upgrade now allows Allegroto monitor patient coagulation therapy in addition to testing for glycemic control, kidney function, anemia, gout, and cardiac risk with a full lipids panel. PT/INR is just one of 18 tests for the Allegro platform, including HbA1c, cholesterol, triglycerides, glucose, creatinine, UACR, hemoglobin, hematocrit, and uric acid. The Allegro analyzer and the new PT/INR test are available for purchase in CE-regulated countries.

Related Links:
Nova Biomedical


Print article

Channels

Molecular Diagnostics

view channel
Image: Blood smear from a P. falciparum culture: several red blood cells have ring stages inside them while close to the center is a schizont and on the left a trophozoite (Photo courtesy of Wikimedia Commons)

Panel of MicroRNAs Differentiates Uncomplicated and Severe Malaria in Children

MicroRNAs (miRNAs), which are rapidly released from damaged tissues into the host fluids, constitute a promising biomarker for the prognosis of severe malaria. MiRNAs comprise a class of about 20 n... Read more

Pathology

view channel
Image: The Leica Bond III stainer is fully automated Immunohistochemical and In Situ Hybridization (IHC and ISH stainer) (Photo courtesy of Leica Biosystems).

Mismatch Repair/Microsatellite Instability Evaluated Using Cytology Effusion Specimens

DNA mismatch repair (MMR) status is routinely assessed in colorectal and endometrial carcinoma as a method of cancer prevention, surveillance in patients with Lynch syndrome and their families, and for... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.